HLA-DR/CII PEPTIDE COMPLEXES FOR TREATING ARTHRITIS

Register WIPO Patent
Application Number EP2020072280
Publication Number 2021/028347
Status In Force
Filing Date 2020-08-07
Publication Date 2021-02-18
Owner FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Germany)
Inventor
  • Nguyen Do, Dr. Nhu
  • Urbonaviciute, Vilma
  • Cienciala, Sylvia
  • Holmdahl, Prof. Rikard
  • Burkhardt, Prof. Dr. Harald

Abstract

[145] The present invention relates to HLA-DR/CII peptide complexes comprising a chondroitinbinding peptide at the C-terminal end of the polypeptide comprising the H LA-DR alpha chain and/or the H LA-DR beta chain, wherein the Cll peptide is fused to the N-terminus of the H LA-DR alpha chain or the H LA-DR beta chain by a linker peptide, for use in treating chronic inflammatory disease, such as arthritis, in human patients. The lysines in the Cll peptide, particularly the first lysine in the Cll peptide, may be post-translationally modified. The invention further relates to methods of producing said HLA-DR/CII peptide complexes in mammalian cells.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61P 37/00 - Drugs for immunological or allergic disorders